Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close: 6.59 USD
Market cap: 116.45M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Related news

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen to Announce Second Quarter Financial Results on August 4, 2026

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

Exagen